beta-Cyclodextrin methyl ethers:Exports & Compliance White Paper 2026

I. Executive Summary

Methyl-beta-cyclodextrin, also described as beta-cyclodextrin methyl ethers and registered under CAS 128446-36-6, is a randomly methylated derivative of the seven-unit cyclic oligosaccharide beta-cyclodextrin. Partial methylation of the hydroxyl groups converts a poorly soluble parent macrocycle into a freely water-soluble host molecule that still retains a lipophilic cavity, which is why it appears both as a solubilising excipient candidate in formulation development and, very widely, as a cholesterol-depleting reagent in cell biology research. Material sold into the research channel is supplied as RUO, Research Use Only: it has no approved therapeutic indication as supplied, it is not a finished consumer product, and it is not intended for human or veterinary use. This paper provides no dosing information and makes no therapeutic or health claims.

The commercial difficulty with this material is that it is not a single structure. It is a population of molecules carrying different numbers of methyl groups at different positions, and the average degree of substitution is a summary statistic that hides the distribution. Batch-to-batch drift in that distribution is the single largest source of customer complaint in this category, because it changes complexation behaviour, surface activity and cholesterol affinity even when the average assay looks identical. Everything else in the specification, including residual methylating agent, chloride, heavy metals, residual solvent, moisture and microbial and endotoxin limits, is downstream of getting the substitution distribution right and proving that it repeats.

Regulatory positioning is therefore the defining commercial decision. A supplier must decide deliberately whether a campaign is RUO-grade research supply or a GMP or excipient-grade programme run to ICH Q7, supported by a drug master file, aligned to the applicable USP/NF and Ph. Eur. cyclodextrin monographs, and assessed for elemental impurities under ICH Q3D and for genotoxic impurities under ICH M7 reasoning. Buyers in the research channel care about reproducibility documentation; buyers in the regulated channel care about the full quality system, and conflating the two is the most common strategic error made in this category.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Beta-cyclodextrin is a cyclic oligosaccharide of seven alpha-1,4-linked D-glucose units arranged as a truncated cone. The outer surface carries hydroxyl groups and is hydrophilic, while the internal cavity is relatively apolar and hosts guest molecules through inclusion complexation driven by hydrophobic interaction, van der Waals contact and the energetic gain of releasing ordered water from the cavity. No covalent bond is formed with the guest, which is why cyclodextrins behave as reversible solubilising hosts rather than as reactants.

• Substitution Pattern and Cavity Consequences: Native beta-cyclodextrin presents twenty-one hydroxyls, seven primary at C6 and fourteen secondary at C2 and C3. Methylation replaces a fraction of them with methoxy groups, breaking the intramolecular hydrogen-bond network that makes the parent macrocycle sparingly soluble. Commercial water-soluble grades typically carry roughly eleven to fourteen methyl groups per macrocycle, but the position matters as much as the count: methylation at the secondary rim widens and flexes the cavity entrance, altering association constants and selectivity between lots.
• Cholesterol Affinity as Market Context: Methylated beta-cyclodextrin has a high affinity for cholesterol, and this is the reason it is purchased in such volume as a cholesterol-depleting reagent in cell biology and membrane research. That application is legitimate market context for a supplier to understand and serve. It is not a basis for any health or therapeutic representation, and the material remains RUO in the research channel.

2.2 Synthesis and Manufacturing Technologies

Manufacture has two clearly separated stages, and the quality risk sits in both. The first is enzymatic production and isolation of the parent cyclodextrin from starch. The second is controlled methylation and the purification that removes reagent, salt and solvent residues. Suppliers who buy in crude beta-cyclodextrin and perform only the second stage frequently cannot explain lot variability they did not introduce.

• CGTase Cyclisation of Starch: Beta-cyclodextrin is produced from starch, commonly potato, corn or tapioca, using cyclodextrin glycosyltransferase from Bacillus species under controlled liquefaction and cyclisation conditions. The reaction mixture contains alpha, beta and gamma cyclodextrins plus linear dextrins, so isolation relies on selective complexation or crystallisation, followed by removal of reducing sugars, dextrins and protein, and control of the microbiological burden before drying.
• Methylation, Quench and Finishing: Partial methylation is carried out under basic conditions using an alkylating agent such as dimethyl sulfate or methyl iodide, with the target substitution level managed through stoichiometry, temperature, addition profile and reaction time. The decisive operations are the quench of residual alkylating agent, removal of inorganic salt by diafiltration or ultrafiltration and ion exchange, decolourisation, and finishing by spray drying or lyophilisation to the required moisture and powder form.

2.3 Core Application Matrix

• Solubilising Excipient Development: Used in RUO formulation screening and in excipient-grade programmes to raise the apparent aqueous solubility and stability of poorly soluble compounds through inclusion complexation, with substitution distribution treated as a critical material attribute.
• Cholesterol-Depletion Research Reagent: The dominant research-channel outlet, supplied as RUO material to cell biology, membrane and trafficking research. No protocols, concentrations or dosing are provided by the supplier, and no therapeutic or health claim attaches to the material.
• Cell Culture, Analytical and Reference Uses: Low-endotoxin and defined-bioburden grades support cell culture work, while characterised lots serve as analytical or impurity reference material for method development and specification setting in customer programmes.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Two demand engines pull this molecule in different directions. Research consumption is steady, price-sensitive and driven by publication and screening activity, which makes reproducibility complaints the main commercial risk. Formulation development interest is growing, driven by the continuing industry need to solubilise poorly soluble new chemical entities and by formulation work on sensitive biological cargos, which pulls demand toward GMP and excipient-grade supply with far heavier documentation.

3.2 Capacity Distribution and Export Flows

Japan is the historical home of cyclodextrin technology and retains strong capability in high-specification and pharmacopoeial-grade material. China has become the volume leader in starch-derived cyclodextrins and their derivatives, competing on cost and increasingly investing in substitution-distribution control. Europe and the United States combine specialty manufacturing, excipient GMP capability and research distribution, and set most of the specification expectations that Asian producers must meet.

3.3 Market Bifurcation and Pricing Dynamics

Price per gram spans an unusually wide range across three tiers: small research packs sold through distributors at high unit margins, kilogram-scale RUO material sold on specification and consistency, and GMP or excipient-grade campaigns priced on quality system cost, validation and filing support. The premium that matters is the reproducibility premium: customers will pay materially more for a supplier who can demonstrate that the substitution distribution of the next lot will match the last one.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Compliance for methylated cyclodextrins is best understood as two distinct operating models. In the research model the obligations are substance notification, honest RUO labelling and a specification the customer can rely on. In the regulated model the obligations expand to excipient or API GMP, compendial alignment, master file support and formal impurity risk assessment, and the two models must be kept separate in documentation, in change control and in commercial communication.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH Position and CLP Assessment: The substance requires a clear European registration position, established through an Only Representative for non-EU manufacturers and supported by a composition definition that acknowledges it as a partially substituted derivative rather than a single congener. CLP assessment should be documented even where no classification is assigned, because buyers and downstream formulators need an evidenced position rather than silence.
• Compendial and Excipient Framework: Regulated supply is aligned to the applicable cyclodextrin monographs in the Ph. Eur. and USP/NF, with in-house specifications justified against that monograph family where no dedicated methylated monograph applies. Excipient-grade campaigns additionally reference IPEC EXCiPACT good manufacturing practice for excipients, and where the material supports a medicinal product, a European master file or active substance master file may be required.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA Status, RUO Labelling and FDA Master Files: Importers must confirm TSCA Inventory listing for the specific methylated derivative and hold Section 13 import certification. Where material is labelled Research Use Only, that labelling has to be supported by the actual circumstances of sale and distribution rather than used as a generic disclaimer, and any move into regulated supply is supported through a Type IV drug master file for excipients.
• Compendial Testing and Impurity Expectations: Regulated and cell-culture customers expect microbial limits and endotoxin testing aligned to USP and Ph. Eur. general chapters, elemental impurity assessment under ICH Q3D with ICP-MS data, residual solvent control under ICH Q3C, and a documented genotoxic impurity position on residual alkylating agent derived from ICH M7 reasoning.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Because the molecule is starch-derived, ESG scrutiny begins with agriculture and ends with water and energy use in purification. Buyers ask about starch origin, genetically modified organism status, vegan suitability and solvent recovery, and ISO 14001 certification of the manufacturing site is normally expected for any campaign above research quantities.

5.1 Carbon Footprint and Circular Economy

The footprint is dominated by upstream starch cultivation and wet milling, by the water and energy demand of enzymatic conversion and of diafiltration and ultrafiltration, and by the drying step, which is far more energy-intensive when lyophilisation is used instead of spray drying. Credible reduction levers are water recycling in purification, heat recovery in drying, and solvent recovery where methylation and purification use organic solvents.

5.2 Sustainable Sourcing and Traceability

Traceability expectations centre on the starch. Customers request botanical source and country of origin, genetically modified organism status and the corresponding documentation, pesticide residue screening, and vegan, halal and kosher certification where the material enters food-adjacent, personal-care or regulated programmes. Suppliers who can issue these documents per lot convert a burden into an advantage.

VI. Supply Chain Resilience and Export Logistics

This is a hygroscopic, amorphous, water-soluble powder. It is not a dangerous good, but it is genuinely moisture-sensitive, and for cell-culture and injectable grades it is contamination-sensitive as well. Logistics design therefore centres on moisture-barrier packaging and, for the highest grades, on low-endotoxin handling rather than on refrigeration.

6.1 Packaging Standards and Moisture/Contamination Control

• Moisture-Barrier Primary Packaging: Material is packed in high-density polyethylene or glass containers with induction seals, inside laminated aluminium foil pouches with desiccant, and shipped in moisture-barrier outer cartons. Water uptake raises the water activity, accelerates microbial growth and shifts the apparent assay, so barrier performance must be qualified and the certificate of analysis must report moisture at release.
• Low-Endotoxin and Cell-Culture Grade Handling: For endotoxin-controlled grades, filling is performed with low-endotoxin water, depyrogenated containers and controlled-environment handling, with endotoxin and bioburden tested on the finished lot. Segregation from commodity-grade material is essential, because a single shared filling line undermines the entire low-endotoxin claim.

6.2 Dangerous Goods Identification and Transit Protocols

Cyclodextrin derivatives are not assigned a UN number and move as general chemicals under IMDG, ADR and IATA with a safety data sheet and standard labelling. Ambient transit is normally acceptable when the moisture barrier is intact, with cool, dry storage at 2-8 C recommended for long-term holding and for endotoxin-controlled grades. Temperature and humidity logging is worth specifying for long tropical sea transits, and consignments should be inspected for pouch integrity on arrival.

VII. Enterprise Global Expansion Strategy Guide

Suppliers that build durable positions in methylated cyclodextrins win on reproducibility evidence rather than on price. The priorities below are the ones that determine whether a supplier is treated as a research vendor or as a development partner.

1. Define the Product by Distribution: Publish a substitution distribution envelope with NMR and LC-MS or MALDI data, not just an average degree of substitution, and demonstrate lot-to-lot overlay so that research customers can trust that the next lot will behave like the last.
2. Build ICH M7-Aligned Impurity Control: Develop and validate a GC method for residual alkylating agent, set a limit justified by acceptable intake, and document the quench and purge rationale, because this is the impurity question that most often blocks qualification in regulated programmes.
3. Separate RUO and Regulated Campaigns: Run RUO and GMP or excipient-grade supply as distinct product lines with separate change control, documentation and packaging, and support regulated customers with master file, IPEC EXCiPACT and ICH Q3D material rather than with assurances.

VIII. Conclusion

Methyl-beta-cyclodextrin is a molecule whose commercial value is entirely a function of controlled heterogeneity. Methylation converts an insoluble parent macrocycle into a water-soluble host, but it does so statistically, and the resulting population of substitution states is what the customer actually buys. Reproducibility of that population, not the average, is the product.

Suppliers who internalise that fact, who combine ISO 9001 and ISO 14001 systems with real distribution analytics, ICH M7-aligned residual alkylating agent control, endotoxin and microbial capability for cell-culture grades, and clean starch-origin documentation covering GMO, vegan, halal and kosher status, will serve both the research and the regulated channel profitably. Material supplied into the research channel remains RUO, Research Use Only, has no approved therapeutic indication as supplied, is not a finished consumer product, and carries no dosing guidance and no therapeutic or health claims.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Methyl-beta-cyclodextrin Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Methyl-beta-cyclodextrin supply chain:

• Japan: The historical home of cyclodextrin science, retaining strong capability in pharmacopoeial-grade and high-specification material, with deep expertise in substitution control and a reputation for consistency that keeps Japanese material specified in regulated and high-end research programmes.
• China: The volume leader in starch-derived cyclodextrins and methylated derivatives, competing on cost with rapidly improving distribution analytics, and increasingly targeting RUO and cell-culture grade export rather than commodity supply alone.
• Europe and the United States: Home to specialty manufacturers, excipient GMP capability and the research distribution infrastructure that supplies academic and industrial laboratories, and the source of most compendial, endotoxin and documentation expectations that shape qualification.